BIO-TECHNE Corp vs VICI Properties Inc — how do they compare? BIO-TECHNE Corp trades at $72.46 (market cap $11.36B), while VICI Properties Inc trades at $22.89 (market cap $25.09B). The key difference: VICI Properties Inc is far larger — about 2.2× BIO-TECHNE Corp's market cap, and VICI Properties Inc pays the higher dividend (8.07%). Which is the better fit depends on your goals — on Pluang, investors hold BIO-TECHNE Corp for 63 Days and VICI Properties Inc for 42 Days on average.
| TECH | VICI | |
|---|---|---|
Market Cap | $11.36B | $25.09B |
Volume | 5,390,331 | 17,066,337 |
Sector | Health | Real Estate |
52-Week High | $72.61 | $31.42 |
52-Week Low | $43.31 | $22.53 |
Typical Hold Time | 63 Days | 42 Days |
Enterprise Value | $11.39B | $42.65B |
Dividend Yield | 0.44% | 8.07% |
Signals from Pluang's Aura AI — not financial advice
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal from moving averages. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026. Revenue for 2025 was $1.22B, with a net income margin of 14.97%. Valuation ratios are elevated, with a P/E of 62.46 and P/S of 9.36. A significant development is the shareholder-approved acquisition by Merck KGaA at $73.00 per share, pending completion.
The outlook is heavily influenced by the pending acquisition, offering a near-term price ceiling. Fundamentals show solid profitability but high valuation multiples. Risks include acquisition deal completion uncertainty and integration challenges. Analyst sentiment is mixed with no sell ratings, but the consensus price target of $65.78 suggests limited upside from current levels, making the stock a hold pending acquisition closure.
VICI Properties trades at $22.64, down 0.4% on the day, with a bearish technical signal driven by moving averages. The stock shows attractive valuation metrics, including a P/E of 8.78 and P/B of 0.85, alongside strong profitability with a net income margin of 67.5%. Recent earnings have been mixed, with a beat in Q1 2026 but misses in Q4 2025 and Q2 2026. The company maintains robust cash flow from operations of $2.51 billion in 2025 and recently announced a dividend of $0.46 per share payable in October 2026.
The outlook for VICI is supported by solid fundamentals and a 75% analyst buy rating, with a consensus price target of $28.90 implying significant upside. However, risks include tenant concentration concerns, as highlighted in recent news, and the bearish technical trend. The stock offers value and income potential but faces headwinds from market sentiment and interest rate sensitivity.
Trailing returns across standard periods
Latest headlines on both assets
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →VICI Properties is an S&P 500 experiential real estate investment trust (REIT) that owns one of the largest portfolios of market-leading gaming, hospitality, and entertainment destinations, including Caesars Palace and MGM Grand. It utilizes a long-term, triple-net lease model to provide stable, inflation-protected income, serving as the primary landlord for the 'experience economy' while diversifying into non-gaming sectors like wellness, youth sports, and luxury resorts.
Read more on VICI →